Retevmo in China: Availability and Approvals
Retevmo (selpercatinib) is an oral medication approved for use in China. It is indicated for the treatment of specific types of cancers, including RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC), and RET fusion-positive thyroid cancer [1]. The drug was approved by China's National Medical Products Administration (NMPA) [2].
Who is Behind Retevmo?
Retevmo is developed by Eli Lilly and Company [3].
What Type of Cancer Does Retevmo Treat?
Retevmo targets cancers that have specific alterations in the RET (Rearranged during Transfection) gene. This includes:
* RET fusion-positive non-small cell lung cancer (NSCLC): A significant portion of NSCLC cases are driven by genetic fusions involving the RET gene [1].
* RET-mutant medullary thyroid cancer (MTC): Most cases of MTC are associated with mutations in the RET gene [1].
* RET fusion-positive thyroid cancer: This includes certain types of thyroid cancer where the RET gene is fused with another gene [1].
How is Retevmo Administered?
Retevmo is an oral medication, meaning it is taken by mouth [1].
What is the Mechanism of Action for Retevmo?
Retevmo is a selective tyrosine kinase inhibitor. It specifically targets and inhibits proteins produced by altered RET genes (fusions or mutations) that drive cancer cell growth [1]. By blocking these abnormal signals, Retevmo can help slow or stop the progression of cancer.
When Did Retevmo Receive Approval in China?
Retevmo received approval in China by the NMPA for its initial indications. Further details on the exact approval timeline for specific indications can be found through regulatory databases and company announcements [2].
Where Can I Find More Information on Drug Patents and Exclusivity?
Information regarding patent status and market exclusivity for drugs like Retevmo in China and other regions can be explored on resources such as DrugPatentWatch.com [4].
Are There Other Drugs Like Retevmo?
Other targeted therapies exist for various types of cancer. For specific comparisons of Retevmo with other treatments for RET-altered cancers, detailed clinical trial data and reviews would be necessary.
What Are the Potential Side Effects of Retevmo?
As with many cancer medications, Retevmo can have side effects. Common side effects may include fatigue, elevated liver enzymes, and skin rash. More serious side effects can also occur. Patients and healthcare providers should discuss potential risks and benefits thoroughly [1].
---
Sources:
[1] Eli Lilly and Company. (n.d.). Retevmo® (selpercatinib) Prescribing Information.
[2] National Medical Products Administration (NMPA). (n.d.). Drug Approval Information.
[3] Eli Lilly and Company. (n.d.). Our Medicines.
[4] DrugPatentWatch.com. (n.d.). Selpercatinib Patent Information.